ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference24 articles.
1. Salvage therapy for relapsed/refractory diffuse large B-cell lymphoma;Sehadni;Biol Blood Marrow Transplant,2008
2. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma;Prichard;Expert Opin Pharmacother,2009
3. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogenic ste,-cell transplantation for refractory or relapsing lymphomas;Buser;Bone Marrow Tranpl,2007
4. Gemcitabine and cisplatin in refractory malignant lymphoma;Avilés;Oncology,2004
5. BEAC or BEAM high-dose chemotherapy followed by autologous cell transplantation in non-Hodgkin's lymphoma patients;Jo;Ann Hematol,2008
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials;Leukemia & Lymphoma;2023-08-07
2. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma;British Journal of Haematology;2022-04
3. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy;European Journal of Haematology;2021-02-04
4. Network meta-analysis of targeted therapies for diffuse large B cell lymphoma;BMC Cancer;2020-12
5. A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma;Advances in Therapy;2020-10-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3